Regeneron holds off copies of $6bn eye treatment

Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar

24 October 2024 Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation

Big Pharma

Regeneron prevails in eye treatment dispute and immediately launches new suit

2 January 2024 District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.

Americas

Regeneron targets almost 50 patents in suit against Sandoz

29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.